ÍÃ×ÓÏÈÉú

Last week, the Food and Drug Administration (FDA) emergency use authorization for the first breathalyzer test designed to detect COVID-19 in adults. The test, given under the supervision of a health care provider, can detect the virus in breath samples in under three minutes. The FDA provided additional information in a . On April 19, the agency against misinterpreting the results of noninvasive prenatal screening tests. The FDA said the tests are not intended to diagnose genetic abnormalities, and none have received FDA authorization. The agency also it is considering revising its opioid disposal requirements and is on its draft mail-back plan.